<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163016">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01766596</url>
  </required_header>
  <id_info>
    <org_study_id>Creuzot-Garcher PHRC IR 2009</org_study_id>
    <nct_id>NCT01766596</nct_id>
  </id_info>
  <brief_title>Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Cohort)</brief_title>
  <acronym>3C</acronym>
  <official_title>Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Cohort): Seek Correlations Between Signs of Neurological and Vascular Degeneration and Signs of Ocular Aging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study proposed in Dijon is above all to focus on the possible relationship
      between age-related ocular pathologies (AMD and glaucoma) and et les degenerative
      neurological and cardiac pathologies.

      The principal objective is to seek in subjects who have undergone cerebral MRI and
      echocardiography, associations between the thickness of postganglionic fibers measured by
      Optical Coherence Tomography at the 7th year (n=1500) and signs of cerebral impairment
      (psycho-cognitive tests, circulation time, MRI signs). This association will be studied
      after taking into account the principal environmental (particularly dietary) and genetic
      risk factors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2009</start_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Measure the mean thickness of postganglionic fibers</measure>
    <time_frame>T=7 years of the 3C cohort</time_frame>
    <description>Measure the thickness of postganglionic fibers by Optical Coherence Tomography in the 4 quadrants of the peripapillary sclera.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>AMD</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>3C cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Optical Coherence Tomography</intervention_name>
    <arm_group_label>3C cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persons who have given their written consent

          -  Persons who are taking part in the Dijon 3C study

        Exclusion Criteria:

          -  Persons who are not registered with social security agency

          -  Persons who are unable to sit upright during a consultation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Catherine CREUZOT-GARCHER</last_name>
    <phone>3 80 29 51 73</phone>
    <phone_ext>33</phone_ext>
    <email>catherine.creuzot-garcher@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine CREUZOT-GARCHER</last_name>
      <phone>3 80 29 51 73</phone>
      <phone_ext>33</phone_ext>
      <email>catherine.creuzot-garcher@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine CREUZOT-GARCHER</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain BRON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie PASSEMARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 10, 2013</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ophthalmology</keyword>
  <keyword>Age-related ocular pathologies</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
